Strengths and Limitations of Commercial Tests for Hepatitis C Virus RNA Quantification
Open Access
- 1 January 2004
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 42 (1) , 421-425
- https://doi.org/10.1128/jcm.42.1.421-425.2004
Abstract
The sensitivity of the Roche COBAS Monitor v.2.0 test was slightly better than that of the Bayer bDNA 3.0 test, but the Monitor test underquantified specimens by 2.5- to 10.6-fold even at relatively low hepatitis C virus RNA concentrations. Dilution prior to assay minimally decreased the reproducibility of the Monitor assay, leading to the recommendation for all specimens to be diluted 1:100 prior to testing by this assay.Keywords
This publication has 19 references indexed in Scilit:
- Comparison of Methodologies for Quantification of Hepatitis C Virus (HCV) RNA in Patients Coinfected with HCV and Human Immunodeficiency VirusClinical Infectious Diseases, 2002
- Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in SerumJournal of Clinical Microbiology, 2002
- Performance of the New Bayer VERSANT HCV RNA 3.0 Assay for Quantitation of Hepatitis C Virus RNA in Plasma and Serum: Conversion to International Units and Comparison with the Roche COBAS Amplicor HCV Monitor, Version 2.0, AssayJournal of Clinical Microbiology, 2002
- Performance Characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit Assay and the National Genetics Institute HCV Superquant AssayJournal of Clinical Microbiology, 2002
- Comparative Evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR Version 2.0 Assays for Quantification of Hepatitis C Virus RNA in SerumJournal of Clinical Microbiology, 2002
- Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNAVox Sanguinis, 1999
- Early Hepatitis C Virus-Rna Responses Predict Interferon Treatment Outcomes in Chronic Hepatitis CHepatology, 1998
- Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparisonHepatology, 1997
- Loss of serum HCV RNA at week 4 of interferon-α therapy is associated with more favorable long-term response in patients with chronic hepatitis CJournal of Medical Virology, 1995
- Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-α therapyDigestive Diseases and Sciences, 1995